Serious adverse events were observed in 32 patients in the pexidartinib group (52.5%) (one case each of erythema, vomiting, lactate dehydrogenase elevation, dizziness, periorbital edema, anemia, and neutropenia; two cases each of arthralgia, hyponatremia, and AST/ALT elevation; three cases of hypertension; four cases of alkaline phosphatase elevation; and six cases of AST and ALT elevation) (8). This evidence concerns the gene GPT and Decreased total neutrophil count.